Drug Search Results
More Filters [+]

DWP-213388

Alternative Names: DWP-213388, DWP213388, DWP 213388, DWJ-213, DWJ213
Latest Update: 2023-04-27
Latest Update Note: News Article

Product Description

Mechanisms of Action: IL2 Inhibitor,Btk Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Daewoong
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for DWP-213388

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Autoimmune Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DW_DWP213388101

P1

Not yet recruiting

Autoimmune Diseases

2024-02-20

28%

Recent News Events